# Bevacizumab for the Treatment of Corneal Neovascularization

> **NCT00992849** · PHASE2 · UNKNOWN · sponsor: **Chang Gung Memorial Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Corneal Neovascularization

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00992849
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-05
- **Primary completion:** 2010-04
- **Final completion:** 2012-04
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2009-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992849, "Bevacizumab for the Treatment of Corneal Neovascularization". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00992849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*